Pharming Group (PHGUF) Rating Lowered to Sell at Zacks Investment Research
Pharming Group (OTCMKTS:PHGUF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday.
According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “
PHGUF stock opened at $1.20 on Tuesday. Pharming Group has a twelve month low of $0.76 and a twelve month high of $1.96. The stock has a market cap of $723.77 million, a P/E ratio of -6.67 and a beta of 2.92. The company has a debt-to-equity ratio of 3.14, a quick ratio of 1.19 and a current ratio of 1.51.
About Pharming Group
Pharming Group N.V., a specialty pharmaceutical company, develops and produces human therapeutic proteins for the treatment of rare diseases and unmet medical needs. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, European Union countries, Norway, Iceland, and Liechtenstein.
Recommended Story: What is a Stop Order?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.